Table 1.
Characteristics of eligible cervical carcinoma patients in the raw and propensity score-matched dataset
| Characteristics | Raw dataset (n = 78) | Matched dataset (n = 58) | ||||
|---|---|---|---|---|---|---|
| Nab-paclitaxelª (n = 54) | Paclitaxelb (n = 24) |
P | Nab-paclitaxelª (n = 37) | Paclitaxelb (n = 21) |
P | |
| Age, mean ± SD years | 51.65 ± 9.968 | 52.38 ± 7.923 | 0.753 | 52.73 ± 9.556 | 52.81 ± 8.370 | 0.975 |
| Stage, n (%) | 0.298 | 0.707 | ||||
| IVB | 16 (29.6) | 10 (41.7) | 14 (37.8) | 9 (42.9) | ||
| Recurrence | 38 (70.4) | 14 (58.3) | 23 (62.2) | 12 (57.1) | ||
| Pathology, n (%) | 0.100 | 0.552 | ||||
| Squamous carcinoma | 45 (83.3) | 16 (66.7) | 29 (78.4) | 15 (71.4) | ||
| Non-squamous carcinoma | 9 (16.7) | 8 (33.3) | 8 (21.6) | 6 (28.6) | ||
| ECOG PS, n (%) | 0.383 | 0.822 | ||||
| 0 | 17 (31.5) | 10 (41.7) | 13 (35.1) | 8 (38.1) | ||
| 1 | 37 (68.5) | 14 (58.3) | 24 (64.9) | 13 (61.9) | ||
| Sites of disease, n (%) | 0.406 | 0.977 | ||||
| No distant metastasis | 26 (48.1) | 14 (58.3) | 21 (56.8) | 12 (57.1) | ||
| Distant metastasis | 28 (51.9) | 10 (41.7) | 16 (43.2) | 9 (42.9) | ||
| Prior surgery, n (%) | 0.698 | 0.822 | ||||
| No | 34 (63.0) | 14 (58.3) | 24 (64.9) | 13 (61.9) | ||
| Yes | 20 (37.0) | 10 (41.7) | 13 (35.1) | 8 (38.1) | ||
| Prior radiotherapy, n (%) | 0.583 | 0.685 | ||||
| No | 52 (96.3) | 22 (91.7) | 35 (94.6) | 19 (90.5) | ||
| Yes | 2 (3.7) | 2 (8.3) | 2 (5.4) | 2 (9.5) | ||
| Prior chemoradiotherapy, n (%) | 0.110 | 0.544 | ||||
| No | 34 (63.0) | 20 (83.3) | 27 (73.0) | 17 (81.0) | ||
| Yes | 20 (37.0) | 4 (16.7) | 10 (27.0) | 4 (19.0) | ||
| Combined radiotherapy, n (%) | 0.819 | 0.875 | ||||
| No | 24 (44.4) | 10 (41.7) | 15 (40.5) | 8 (38.1) | ||
| Yes | 30 (55.6) | 14 (58.3) | 22 (59.5) | 13 (61.9) | ||
NotesaPatients received nab-paclitaxel plus cisplatin or carboplatin. bPatients received paclitaxel plus cisplatin or carboplatin
Abbreviations SD, standard deviation; ECOG PS, Eastern Cooperative Oncology Group performance status